Generation and Application of a Novel Monoclonal Antibody to UBQLN4 to Characterize the dsDNA Damage Response

Abstract: The high-throughput screening system illustrated here produced a UBQLN4 recombinant monoclonal antibody capable of binding to its target protein with high specificity and affinity. This specificity was judged by utilizing an adapted "pillar" system and we utilized the pillars for "independent antibodies," "complementary assays," and "genetic strategies." Given this specificity, we were also able to show utility in other assays, such as flow cytometry and a 6-plex multiplex IHC assay. This antibody is well suited to continue studying the role of UBQLN4 in DNA damage response and its relationship with other proteins in this pathway.

Speaker: Dr. Brian McWilliams, Senior Manager, Validation

Dr. McWilliams received his undergraduate degree in Biochemistry from Oklahoma State University in 2001. His Ph.D. was completed with Dr. Joseph Petrosino at Baylor College of Medicine, where he studied vaccine design and diagnostics for bacterial pathogens Bacillus anthracis and Francisella tularensis. After a brief post-doc at The University of Texas – Medical Branch in Galveston, TX, he joined Bethyl Laboratories.

He is currently the Senior Manager, Validation at Fortis Life Sciences, serving to maintain the existing catalog of Bethyl antibodies and validate new polyclonal and monoclonal antibody products from the R&D pipeline.

Watch this on-demand poster session: